The Incidence, Mortality, and Survival of Breast Cancer per HER2/HR Status in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2018-2022 Database Analysis
Author(s)
Vlad Zah, DPhil, Filip Stanicic, PhD (c), Dimitrije Grbic, PhD (c).
ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
Presentation Documents
OBJECTIVES: Surveillance, Epidemiology, and End Results (SEER; released April 2025) data were used to investigate the breast cancer (BC) burden in the US.
METHODS: 17 cancer registries (January 2018 - December 2022) were analyzed with SEER*Stat. BC patients were the target population. Outcomes included crude incidence and mortality rates (per 100,000 population) and survival.
RESULTS: 377,387 BC patients were captured. The most common were HER2-/HR+ subtypes (59.49%) and localized stage (53.51%). Patients were mostly 20-64 years old (55.23%), females (99.21%), non-Hispanic Whites (62.29%), married (55.21%), metropolitan county residents (90.38%), and had $65,000-90,000 annual household income (AHI) (43.93%). The BC incidence was 86.24/100,000. The most common was localized HER2-/HR+ BC (34.99/100,000). Across demographic groups, the rates were higher in the elderly (251.50/100,000), females (170.06/100,000), non-Hispanic Whites (106.56/100,000), non-metropolitan area residents (86.96/100,000), and >$120,000 AHI (94.26/100,000). Incidence increased from 2018 (85.05/100,000) to 2022 (90.05/100,000), with a slight decline in 2020 (77.95/100,000). The BC mortality was 37.58/100,000. The highest rates per group were reported for localized HER2-/HR+ BC (6.99/100,000), elderly (199.58/100,000), females (73.87/100,000), non-Hispanic Whites (53.12/100,000), non-metropolitan area residents (48.68/100,000), and <$40,000 AHI (53.48/100,000). Mortality consistently increased from 2018 (34.03/100,000) to 2022 (41.92/100,000). In 2018, the 4-year survival rate was 88.58%. However, distant BC had a much lower rate (37.05%), especially if HER2-/HR+ status was undetermined (10.70%) or the HER2-/HR- subtype was diagnosed (15.15%). Among demographic groups, the lowest 4-year rates were reported for males (80.77%), non-Hispanic Blacks (83.00%), and non-metropolitan county residents (85.08%). The 1-year rates between 2018 (96.86%) and 2021 (96.57%) were similar. The lowest 1-year survival in 2021 was observed for distant BC (69.38%), especially for those with undetermined HER2/HR status (29.49%).
CONCLUSIONS: This study may indicate high BC burden in the US. Incidence and mortality rates are high and increasing each year, while the survival of specific subtypes/stages remains low.
METHODS: 17 cancer registries (January 2018 - December 2022) were analyzed with SEER*Stat. BC patients were the target population. Outcomes included crude incidence and mortality rates (per 100,000 population) and survival.
RESULTS: 377,387 BC patients were captured. The most common were HER2-/HR+ subtypes (59.49%) and localized stage (53.51%). Patients were mostly 20-64 years old (55.23%), females (99.21%), non-Hispanic Whites (62.29%), married (55.21%), metropolitan county residents (90.38%), and had $65,000-90,000 annual household income (AHI) (43.93%). The BC incidence was 86.24/100,000. The most common was localized HER2-/HR+ BC (34.99/100,000). Across demographic groups, the rates were higher in the elderly (251.50/100,000), females (170.06/100,000), non-Hispanic Whites (106.56/100,000), non-metropolitan area residents (86.96/100,000), and >$120,000 AHI (94.26/100,000). Incidence increased from 2018 (85.05/100,000) to 2022 (90.05/100,000), with a slight decline in 2020 (77.95/100,000). The BC mortality was 37.58/100,000. The highest rates per group were reported for localized HER2-/HR+ BC (6.99/100,000), elderly (199.58/100,000), females (73.87/100,000), non-Hispanic Whites (53.12/100,000), non-metropolitan area residents (48.68/100,000), and <$40,000 AHI (53.48/100,000). Mortality consistently increased from 2018 (34.03/100,000) to 2022 (41.92/100,000). In 2018, the 4-year survival rate was 88.58%. However, distant BC had a much lower rate (37.05%), especially if HER2-/HR+ status was undetermined (10.70%) or the HER2-/HR- subtype was diagnosed (15.15%). Among demographic groups, the lowest 4-year rates were reported for males (80.77%), non-Hispanic Blacks (83.00%), and non-metropolitan county residents (85.08%). The 1-year rates between 2018 (96.86%) and 2021 (96.57%) were similar. The lowest 1-year survival in 2021 was observed for distant BC (69.38%), especially for those with undetermined HER2/HR status (29.49%).
CONCLUSIONS: This study may indicate high BC burden in the US. Incidence and mortality rates are high and increasing each year, while the survival of specific subtypes/stages remains low.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH244
Topic
Epidemiology & Public Health, Real World Data & Information Systems
Disease
Oncology